SHA-68
(IUPAC ) ime
N -[(4-fluorofenil)metil]-3-okso-1,1-difenil-5,6,8,8a-tetrahidro-[1,3]oksazolo[3,4-a]pirazin-7-karboksamid
Klinički podaci
Identifikatori
ATC kod
nije dodeljen
PubChem [ 1] [ 2] 11374217
Hemijski podaci
Formula
C 26 H 24 F N 3 O 3
Mol. masa
445.484 g/mol
SMILES
eMolekuli PubHem
InChI InChI=1S/C26H24FN3O3/c27-22-13-11-19(12-14-22)17-28-24(31)29-15-16-30-23(18-29)26(33-25(30)32,20-7-3-1-4-8-20)21-9-5-2-6-10-21/h1-14,23H,15-18H2,(H,28,31) Y Y
Farmakoinformacioni podaci
Trudnoća
?
Pravni status
SHA-68 je lek koji deluje kao selektivni , ne-peptidni antagonist neuropeptidnog S receptora NPSR . U životinjskim studijama on izaziva uznemirenost, i blokira stimulišuće dejstvo neuropeptida S.[ 3] [ 4]
↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.” . Drug Discov Today 15 (23-24): 1052-7. DOI :10.1016/j.drudis.2010.10.003 . PMID 20970519 . edit ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4 : 217-241. DOI :10.1016/S1574-1400(08)00012-1 . ↑ Fukatsu K, Nakayama Y, Tarui N, Mori M, Matsumoto H, Kurasawa O, Banno H. Bicyclic Piperazine Compound and Use Thereof. PCT Patent WO 2005/021555 A1. Published 26.08.2004
↑ Okamura N, Habay SA, Zeng J, Chamberlin AR, Reinscheid RK (June 2008). „Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor”]. The Journal of Pharmacology and Experimental Therapeutics 325 (3): 893–901. DOI :10.1124/jpet.107.135103 . PMC 2583099 . PMID 18337476 .
Šablon:Neuropeptidni ligandi
